Abstract
Background Introgression of the insect bacterium Wolbachia into Aedes aegypti mosquito populations been shown in randomised and non-randomised trials to reduce the incidence of dengue in treated communities, however evidence for the real-world effectiveness of large-scale Wolbachia mosquito deployments for arboviral disease control in endemic settings is still limited and no effectiveness studies have been conducted for chikungunya virus. A large Wolbachia (wMel strain) program was implemented in 2017 in Rio de Janeiro, Brazil. Here we assess the impact of the release program on dengue and chikungunya incidence.
Methods and findings The program released 67 million wMel infected mosquitoes across 28,489 release locations over a 86.8km2 area in Rio de Janeiro between August 2017 and the end of 2019. Following releases, mosquitoes were trapped and the presence of wMel determined. To assess the impact of the release program on dengue and chikungunya incidence, we used spatiotemporally explicit models applied to geocoded dengue (N=194,330) and chikungunya cases (N=58,364) from 2010 (2016 for chikungunya) to 2019 from across the city. On average, 32% of mosquitoes collected from the release zones between 1 and 29 months after releases were positive for wMel. Reduced wMel introgression occurred in locations and seasonal periods when dengue and chikungunya cases were historically high. Despite incomplete introgression, we found that the releases were associated with a 38% (95%CI: 32-44%) reduction in dengue incidence and a 10% (95%CI: 4-16%) reduction in chikungunya incidence.
Conclusions Stable establishment of wMel in this diverse, urban setting appears more complicated than has been observed elsewhere. However, even intermediate levels of wMel appear to reduce the incidence of two different arboviruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the ERC (grant n. 804744) and the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Brazilian National Institutional Review Board (CONEP -59175616.2.0000.0008).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These authors jointly supervised the work
Data Availability
All data produced in the present study are available upon reasonable request to the authors
